Cellestia
WE ASPIRE TO
We aspire to reach true breakthroughs in cancer treatments and therapies that will ultimately lead to a cure for previously incurable cancers.
WE ARE RESOLUTE IN OUR
WE EXTEND AND IMPROVE
WE ARE RELENTLESS IN OUR PURSUIT OF
WE DO WHATEVER IT TAKEs TO
We hold each other responsible and accountable to the vision and goals we share as we carve our own path forward.
2012
First patent application filed.
2015
Michael Bauer joins, the Management Team is extended,
and the HQ move to Basel.
2017
First patient treated in December.
2019
Safety and Efficacy Data available.
2008
Project starts with Raj Lehal’s doctoral thesis.
2014
Cellestia is founded in Lausanne by Prof. Freddy Radtke
and Raj Lehal.
2016
CB-103 development begins.
2018
CHF 29 m raised in private equity.
2020
Planning start of Ph ll Clinical Program.
2008
Project starts with Raj Lehal’s doctoral thesis.
2012
First patent application filed.
2014
Cellestia is founded in Lausanne by Prof. Freddy Radke and Raj Lehal.
2015
Michael Bauer joins, the Management Team is extended, and the HQ move to Basel.
2016
CB-103 development begins.
2017
First patient treated in December.
2018
CHF 29 m raised in private equity.
2019
Safety and Efficacy Data available.
2020
Planning start of Ph ll Clinical Program.
RAJ’S STORY
MICHAEL’S STORY
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.